The triazole antifungal agents: a review of itraconazole and fluconazole

Pharmacotherapy. 1990;10(2):146-53.

Abstract

Fluconazole and itraconazole are two investigational triazole antifungal agents that are currently undergoing clinical trials in the United States. Both are active orally, have favorable pharmacokinetics (i.e., good bioavailability, long half-life, low plasma protein binding), and possess activity against several systemic fungal pathogens. In addition, preliminary information suggests that these agents are substantially less toxic than currently available azole compounds. Fluconazole and, to a lesser degree, itraconazole have been shown to be highly effective for the treatment of cryptococcal meningitis. The potential for drug interactions is much lower with these agents compared to drugs such as ketoconazole.

Publication types

  • Clinical Trial
  • Comparative Study
  • Review

MeSH terms

  • Antifungal Agents / adverse effects
  • Antifungal Agents / pharmacokinetics*
  • Antifungal Agents / pharmacology
  • Aspergillus / drug effects
  • Candida albicans / drug effects
  • Chemical Phenomena
  • Chemistry
  • Clinical Trials as Topic
  • Cryptococcus neoformans / drug effects
  • Fluconazole / adverse effects
  • Fluconazole / pharmacokinetics
  • Fluconazole / pharmacology
  • Fluconazole / therapeutic use*
  • Half-Life
  • Humans
  • Itraconazole
  • Ketoconazole / adverse effects
  • Ketoconazole / analogs & derivatives*
  • Ketoconazole / pharmacokinetics
  • Ketoconazole / pharmacology
  • Ketoconazole / therapeutic use
  • Metabolic Clearance Rate

Substances

  • Antifungal Agents
  • Itraconazole
  • Fluconazole
  • Ketoconazole